Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease

Eur Respir J. 2021 Feb 25;57(2):2003079. doi: 10.1183/13993003.03079-2020. Print 2021 Feb.

Authors

Kate M O'Shea^{1

2}, Orla M O'Carroll^{3

2}, Catherine Carroll³, Brenda Grogan^{1

3}, Anna Connolly³, Lynda O'Shaughnessy³, Trevor T Nicholson³, Charles G Gallagher^{1

3}, Edward F McKone^{4

3}

Affiliations

¹ School of Medicine, University College Dublin, Dublin, Ireland.
² Equal contributions.
³ Dept of Respiratory Medicine, St Vincent's University Hospital, Dublin, Ireland.
⁴ School of Medicine, University College Dublin, Dublin, Ireland emckone@svhg.ie.

PMID: 33154033
DOI: 10.1183/13993003.03079-2020

No abstract available

Publication types

Letter

MeSH terms

Aminophenols / therapeutic use
Benzodioxoles
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Humans
Indoles
Pyrazoles
Pyridines
Pyrrolidines
Quinolones

Substances

Aminophenols
Benzodioxoles
Indoles
Pyrazoles
Pyridines
Pyrrolidines
Quinolones
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
elexacaftor